Inovio Net Tangible Assets vs Net Debt Analysis

INO Stock

USD 1.50 0.03 2.04%

Inovio Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Inovio Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inovio Pharmaceuticals is a good investment. Please check the relationship between Inovio Pharmaceuticals Net Tangible Assets and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

Net Tangible Assets vs Net Debt

Net Tangible Assets vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Inovio Pharmaceuticals Net Tangible Assets account and Net Debt. At this time, the significance of the direction appears to have pay attention.

The correlation between Inovio Pharmaceuticals' Net Tangible Assets and Net Debt is -0.71. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Net Debt in the same time period over historical financial statements of Inovio Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Inovio Pharmaceuticals' Net Tangible Assets and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Inovio Pharmaceuticals are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Net Tangible Assets i.e., Inovio Pharmaceuticals' Net Tangible Assets and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.71

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Inovio Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inovio Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.At this time, Inovio Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 5th of August 2025, Sales General And Administrative To Revenue is likely to grow to about 178.4 K, while Issuance Of Capital Stock is likely to drop about 34.2 M.

	2022	2023	2024	2025 (projected)
Interest Expense	1.3M	1.2M	177.8K	168.9K
Depreciation And Amortization	5.5M	3.5M	3.1M	2.4M

Interest Expense Depreciation And Amortization

Inovio Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Other Current Liab	Other Liab	Non Currrent Assets Other	Other Assets	Long Term Debt	Common Stock Total Equity
Total Assets		-0.26	0.7	0.97	0.76	-0.58	-0.4	0.59	0.76	0.67	0.99	0.75	0.75	0.33	0.88	0.54	0.63	0.6	1.0	-0.32	0.68	-0.25	0.62	0.64	0.07	-0.31
Short Long Term Debt Total	-0.26		-0.25	-0.27	-0.18	0.23	0.64	-0.23	-0.26	0.43	-0.32	0.0	0.09	0.04	-0.39	-0.64	-0.12	-0.51	-0.33	0.8	-0.24	0.82	-0.18	-0.1	0.09	-0.45
Total Current Liabilities	0.7	-0.25		0.58	0.66	-0.08	-0.59	0.81	0.25	0.36	0.69	0.58	0.32	0.29	0.8	0.64	0.78	0.55	0.72	-0.33	0.94	-0.15	0.11	0.11	0.18	-0.38
Total Stockholder Equity	0.97	-0.27	0.58		0.62	-0.71	-0.31	0.48	0.8	0.63	0.97	0.75	0.72	0.12	0.82	0.47	0.42	0.51	0.97	-0.27	0.56	-0.31	0.65	0.68	-0.08	-0.26
Property Plant And Equipment Net	0.76	-0.18	0.66	0.62		-0.11	-0.49	0.66	0.45	0.63	0.75	0.45	0.77	0.7	0.62	0.56	0.85	0.8	0.74	-0.4	0.61	0.07	0.41	0.39	0.56	-0.3
Net Debt	-0.58	0.23	-0.08	-0.71	-0.11		0.1	0.14	-0.89	-0.41	-0.58	-0.58	-0.35	0.24	-0.43	-0.23	0.11	-0.07	-0.58	0.11	-0.2	0.31	-0.82	-0.79	0.27	0.12
Retained Earnings	-0.4	0.64	-0.59	-0.31	-0.49	0.1		-0.45	-0.22	0.05	-0.43	-0.07	-0.08	-0.21	-0.42	-0.98	-0.49	-0.81	-0.43	0.59	-0.54	0.5	-0.13	0.0	-0.22	0.34
Accounts Payable	0.59	-0.23	0.81	0.48	0.66	0.14	-0.45		0.0	0.25	0.59	0.28	0.47	0.27	0.66	0.5	0.65	0.62	0.6	-0.31	0.68	-0.11	-0.17	-0.17	0.25	-0.2
Cash	0.76	-0.26	0.25	0.8	0.45	-0.89	-0.22	0.0		0.58	0.76	0.65	0.57	0.21	0.6	0.35	0.29	0.29	0.76	-0.25	0.38	-0.28	0.94	0.92	0.02	-0.18
Non Current Assets Total	0.67	0.43	0.36	0.63	0.63	-0.41	0.05	0.25	0.58		0.61	0.71	0.8	0.45	0.42	0.07	0.5	0.23	0.61	0.25	0.38	0.42	0.59	0.62	0.29	-0.56
Cash And Short Term Investments	0.99	-0.32	0.69	0.97	0.75	-0.58	-0.43	0.59	0.76	0.61		0.7	0.74	0.3	0.87	0.58	0.6	0.64	1.0	-0.38	0.65	-0.3	0.6	0.61	0.05	-0.28
Net Receivables	0.75	0.0	0.58	0.75	0.45	-0.58	-0.07	0.28	0.65	0.71	0.7		0.49	0.13	0.64	0.2	0.42	0.15	0.73	0.0	0.57	0.01	0.62	0.66	-0.08	-0.22
Common Stock Shares Outstanding	0.75	0.09	0.32	0.72	0.77	-0.35	-0.08	0.47	0.57	0.8	0.74	0.49		0.5	0.48	0.21	0.51	0.55	0.72	-0.06	0.26	0.16	0.5	0.52	0.34	-0.32
Non Current Liabilities Total	0.33	0.04	0.29	0.12	0.7	0.24	-0.21	0.27	0.21	0.45	0.3	0.13	0.5		0.28	0.21	0.83	0.43	0.3	-0.24	0.32	0.22	0.25	0.24	0.67	-0.18
Other Current Assets	0.88	-0.39	0.8	0.82	0.62	-0.43	-0.42	0.66	0.6	0.42	0.87	0.64	0.48	0.28		0.53	0.65	0.45	0.9	-0.36	0.84	-0.43	0.45	0.49	0.03	-0.16
Other Stockholder Equity	0.54	-0.64	0.64	0.47	0.56	-0.23	-0.98	0.5	0.35	0.07	0.58	0.2	0.21	0.21	0.53		0.52	0.85	0.58	-0.59	0.59	-0.52	0.25	0.13	0.17	-0.36
Total Liab	0.63	-0.12	0.78	0.42	0.85	0.11	-0.49	0.65	0.29	0.5	0.6	0.42	0.51	0.83	0.65	0.52		0.61	0.61	-0.35	0.76	0.05	0.23	0.22	0.55	-0.34
Property Plant And Equipment Gross	0.6	-0.51	0.55	0.51	0.8	-0.07	-0.81	0.62	0.29	0.23	0.64	0.15	0.55	0.43	0.45	0.85	0.61		0.61	-0.56	0.42	-0.29	0.21	0.12	0.36	-0.29
Total Current Assets	1.0	-0.33	0.72	0.97	0.74	-0.58	-0.43	0.6	0.76	0.61	1.0	0.73	0.72	0.3	0.9	0.58	0.61	0.61		-0.37	0.68	-0.32	0.6	0.62	0.05	-0.27
Intangible Assets	-0.32	0.8	-0.33	-0.27	-0.4	0.11	0.59	-0.31	-0.25	0.25	-0.38	0.0	-0.06	-0.24	-0.36	-0.59	-0.35	-0.56	-0.37		-0.29	0.45	-0.14	-0.08	-0.21	-0.38
Other Current Liab	0.68	-0.24	0.94	0.56	0.61	-0.2	-0.54	0.68	0.38	0.38	0.65	0.57	0.26	0.32	0.84	0.59	0.76	0.42	0.68	-0.29		-0.16	0.27	0.26	0.21	-0.35
Other Liab	-0.25	0.82	-0.15	-0.31	0.07	0.31	0.5	-0.11	-0.28	0.42	-0.3	0.01	0.16	0.22	-0.43	-0.52	0.05	-0.29	-0.32	0.45	-0.16		-0.17	-0.14	0.36	-0.26
Non Currrent Assets Other	0.62	-0.18	0.11	0.65	0.41	-0.82	-0.13	-0.17	0.94	0.59	0.6	0.62	0.5	0.25	0.45	0.25	0.23	0.21	0.6	-0.14	0.27	-0.17		0.98	0.12	-0.13
Other Assets	0.64	-0.1	0.11	0.68	0.39	-0.79	0.0	-0.17	0.92	0.62	0.61	0.66	0.52	0.24	0.49	0.13	0.22	0.12	0.62	-0.08	0.26	-0.14	0.98		0.08	-0.09
Long Term Debt	0.07	0.09	0.18	-0.08	0.56	0.27	-0.22	0.25	0.02	0.29	0.05	-0.08	0.34	0.67	0.03	0.17	0.55	0.36	0.05	-0.21	0.21	0.36	0.12	0.08		-0.17
Common Stock Total Equity	-0.31	-0.45	-0.38	-0.26	-0.3	0.12	0.34	-0.2	-0.18	-0.56	-0.28	-0.22	-0.32	-0.18	-0.16	-0.36	-0.34	-0.29	-0.27	-0.38	-0.35	-0.26	-0.13	-0.09	-0.17

Click cells to compare fundamentals

Inovio Pharmaceuticals Account Relationship Matchups

Inovio Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	539.8M	495.9M	348.5M	171.0M	113.2M	130.9M
Short Long Term Debt Total	39.0M	33.0M	32.1M	30.2M	11.9M	21.3M
Total Current Liabilities	41.7M	65.7M	96.9M	42.6M	35.3M	24.2M
Total Stockholder Equity	461.1M	399.7M	222.4M	117.3M	68.5M	94.4M
Property Plant And Equipment Net	24.1M	29.0M	18.0M	14.5M	11.8M	7.7M
Net Debt	(211.7M)	(38.1M)	(14.3M)	15.9M	(53.9M)	(51.3M)
Retained Earnings	(906.2M)	(1.2B)	(1.5B)	(1.6B)	(1.7B)	(1.6B)
Accounts Payable	1.5M	28.0M	21.1M	4.6M	6.4M	5.2M
Cash	250.7M	71.1M	46.3M	14.3M	65.8M	34.7M
Non Current Assets Total	68.6M	47.5M	33.3M	17.8M	17.1M	27.8M
Cash And Short Term Investments	411.6M	401.3M	253.0M	145.3M	94.1M	92.4M
Net Receivables	19.1M	8.0M	11.7M	2.4M	1.2M	1.1M
Common Stock Shares Outstanding	169.9M	214.6M	19.9M	22.2M	27.2M	47.3M
Liabilities And Stockholders Equity	539.8M	495.9M	348.5M	171.0M	114.9M	130.9M
Non Current Liabilities Total	36.9M	30.5M	29.3M	11.0M	9.4M	12.0M
Other Current Assets	40.5M	39.1M	50.5M	5.4M	2.5M	2.4M
Other Stockholder Equity	1.4B	1.6B	1.7B	1.7B	1.8B	1.9B
Total Liab	78.6M	96.3M	126.2M	53.6M	46.4M	36.1M
Property Plant And Equipment Gross	24.1M	48.0M	18.0M	35.3M	28.2M	29.6M
Total Current Assets	471.2M	448.4M	315.2M	153.1M	97.8M	103.2M
Accumulated Other Comprehensive Income	(256.2K)	(282.2K)	(698.7K)	(662.6K)	(675.7K)	(641.9K)
Intangible Assets	3.7M	3.1M	2.6M	2.1M	2.4M	2.3M
Other Current Liab	37.9M	35.1M	73.0M	18.7M	26.4M	15.7M
Other Liab	9.1M	206.4K	111.2K	32.0K	36.9K	35.0K
Non Currrent Assets Other	26.0M	1.4M	684.0K	605.3K	3.7M	2.5M
Other Assets	43.6M	1.4M	684.0K	1.0	(1.7M)	(1.6M)
Common Stock Total Equity	101.4K	186.9K	217.4K	253.1K	227.8K	216.4K
Short Term Debt	2.3M	2.6M	2.8M	19.2M	2.5M	2.4M
Common Stock	186.9K	217.4K	253.1K	22.8K	36.1K	34.3K
Property Plant Equipment	12.8M	11.3M	17.5M	7.7M	8.9M	5.2M
Current Deferred Revenue	124.1K	46.6K	21.6K	1.0M	1.2M	2.1M
Short Term Investments	160.9M	330.2M	206.7M	131.0M	28.3M	26.9M
Net Tangible Assets	(10.8M)	447.5M	386.5M	209.7M	241.2M	159.6M
Retained Earnings Total Equity	(739.8M)	(906.2M)	(1.2B)	(1.5B)	(1.3B)	(1.3B)
Capital Surpluse	742.6M	1.4B	1.6B	1.7B	2.0B	2.1B

Pair Trading with Inovio Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inovio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inovio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Inovio Stock

0.65	JNJ	Johnson Johnson	Pair Corr
0.62	ILMN	Illumina	Pair Corr
0.52	MRK	Merck Company	Pair Corr
0.49	PFE	Pfizer Inc Earnings Call Today	Pair Corr
0.45	VRTX	Vertex Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Inovio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inovio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inovio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inovio Pharmaceuticals to buy it.

The correlation of Inovio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inovio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inovio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Inovio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:

How To Invest In Inovio

Details

Is Inovio Stock a good investment?

Details

What is Inovio Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.

To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.15)

Revenue Per Share

0.009

Quarterly Revenue Growth

0.14

Return On Assets

(0.61)

Return On Equity

(1.32)

The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Inovio Net Tangible Assets vs Net Debt Analysis

Net Tangible Assets vs Net Debt

Net Tangible Assets vs Net Debt Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Net Debt

Inovio Pharmaceuticals fundamental ratios Correlations

Inovio Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inovio Pharmaceuticals fundamental ratios Accounts

Pair Trading with Inovio Pharmaceuticals

Moving against Inovio Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets
Other Assets	+ 0.98	Non Currrent Assets Other
Total Stockholder Equity	+ 0.97	Total Assets
Cash And Short Term Investments	+ 0.97	Total Stockholder Equity

Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.89	Net Debt
Non Currrent Assets Other	- 0.82	Net Debt
Property Plant And Equipment Gross	- 0.81	Retained Earnings
Other Assets	- 0.79	Net Debt
Net Debt	- 0.71	Total Stockholder Equity